Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-β1

Haematologica

Volumn 96, Issue 9, 2011, Pages 1302-1309

  Szczepanski, Miroslaw J ^a,b,c   Szajnik, Marta ^a,b   Welsh, Ann ^a,b   Whiteside, Theresa L ^a,b   Boyiadzis, Michael ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Acute myeloid leukemia; Exosomes; Interleukin 15; NK cells; TGF 1

Indexed keywords

CD33 ANTIGEN; CD34 ANTIGEN; INTERLEUKIN 15; NATURAL KILLER CELL RECEPTOR NKG2D; STEM CELL FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOTOXICITY; MALE; MEMBRANE VESICLE; MICROVESICLE; MYELOBLAST; NATURAL KILLER CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; AGED; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; EXOSOMES; FEMALE; HUMANS; INTERLEUKIN-15; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; TRANSFORMING GROWTH FACTOR BETA1;

EID: 80052384534     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.039743     Document Type: Article

References (34)

1. Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461-9.
2. Szczepanski MJ, Szajnik M, Welsh A, Foon KA, Whiteside TL, Boyiadzis M. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol Immunother. 2010;59(1):73-9.
3. Costello RT, Sivori S, Marcenaro E, Lafage- Pochitaloff M, Mozziconacci MJ, Reviron D, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood. 2002;99(10):3661-7.
4. Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood. 2007;109(1):323-30.
5. Groh V, Wu J, Yee C, Spies T. Tumourderived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):679-80.
6. Al-Nedawi K, Meehan B, Rak J. Microvesicles: messengers and mediators of tumor progression. Cell Cycle. 2009;8 (13):2014-8.
7. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P, et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet. 2002;360 (9329):295-305.
8. Bergmann C, Strauss L, Wieckowski E, Czystowska M, Albers A, Wang Y, et al. Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck. 2009;31(3):371-80.
9. Taylor DD, Gercel-Taylor C, Lyons KS, Stanson J, Whiteside TL. T-cell apoptosis and suppression of T-cell receptor/CD3- zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res. 2003;9(14):5113-9.
10. Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, et al. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ. 2008;15(1):80-8.
11. Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 2005;11(3):1010-20.
12. Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ, Whiteside TL. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol. 2009;183(6): 3720-30.
13. Xiang X, Poliakov A, Liu C, Deng ZB, Wang J, Cheng Z, et al. Induction of myeloidderived suppressor cells by tumor exosomes. Int J Cancer. 2009;124(11):2621-33.
14. Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL. Tumorderived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (treg). PLoS One 2010;5(7):e11469.
15. Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007;67(7):2912-5.
16. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96 (13):4075-83.
17. Friberg DD, Bryant JL, Whiteside TL. Measurements of natural killer (NK) Activity and NK-cell quantification. Methods 1996;9(2):316-26.
18. Whiteside TL, Bryant J, Day R, Herberman RB. Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. J Clin Lab Anal. 1990;4 (2):102-14.
19. Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA. 2003;100(7):4120-5.
20. Trotta R, Col JD, Yu J, Ciarlariello D, Thomas B, Zhang X, et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibodydependent cellular cytotoxicity in human NK cells. J Immunol. 2008;181(6):3784-92.
21. Nowbakht P, Ionescu MC, Rohner A, Kalberer CP, Rossy E, Mori L, et al. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood. 2005;105(9):3615-22.
22. Ashiru O, Boutet P, Fernandez-Messina L, Aguera-Gonzalez S, Skepper JN, Vales- Gomez M, et al. Natural killer cell cytotoxicity is suppresssed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res. 2010;70(2):481-9.
23. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol. 2008;180(11):7249-58.
24. Liu C, Yu S, Zinn K, Wang J, Zhang L, Jia Y, et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol. 2006;176(3):1375-85.
25. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci. 2000;113(pt 19):3365-74.
26. Johnstone RM. Exosomes biological significance: a concise review. Blood Cells Mol Dis. 2006;36(2):315-21.
27. Wieckowski E, Whiteside TL. Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles. Immunol Res. 2006;36(1-3):247-54.
28. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010;31(6):220-7.
29. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 secretion and downmodulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 2004;172(12):7335-40.
30. Boyiadzis M, Memon S, Carson J, Allen K, Szczepanski MJ, Vance BA, et al. Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels. Biol Blood Marrow Transplant. 2008;14(3):290-300.
31. Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 1997;99(5):937-43.
32. Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood. 2002;100(10):3633-8.
33. Ranson T, Vosshenrich CA, Corcuff E, Richard O, Muller W, Di Santo JP. IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood. 2003;101(12):4887-93.
34. Benahmed M, Meresse B, Arnulf B, Barbe U, Mention JJ, Verkarre V, et al. Inhibition of TGF-beta signaling by IL-15: a new role for IL-15 in the loss of immune homeostasis in celiac disease. Gastroenterology. 2007;132(3):994-1008.